Overview
- Tatiana Schlossberg, 35, disclosed that oncologists now consider her acute myeloid leukemia terminal after a physician estimated she may have about a year to live.
- She was diagnosed in May 2024 hours after giving birth, with AML carrying a rare Inversion 3 mutation that is linked to poor response to standard therapy.
- Her treatment course included multiple rounds of chemotherapy, two bone‑marrow transplants (first from her sister, then from an unrelated donor), and an experimental CAR‑T trial complicated by severe illness.
- She reported additional complications in September from an Epstein–Barr–related illness that damaged her kidneys and required relearning to walk, with care at NewYork‑Presbyterian/Columbia and Memorial Sloan Kettering.
- In the essay she condemns HHS Secretary Robert F. Kennedy Jr. for research funding cuts, including to mRNA vaccine work, and notes broader NIH reductions and briefly disrupted Columbia funding as examples of destabilized care.